Dyadic International, Inc (NASDAQ:DYAI) shares were up 9.5% during trading on Monday . The company traded as high as $6.74 and last traded at $6.60, approximately 249,385 shares were traded during mid-day trading. An increase of 308% from the average daily volume of 61,159 shares. The stock had previously closed at $6.03.
A number of analysts recently commented on DYAI shares. Noble Financial restated a “buy” rating and issued a $9.00 price objective on shares of Dyadic International in a research report on Monday, July 8th. ValuEngine cut shares of Dyadic International from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st.
Dyadic International (NASDAQ:DYAI) last released its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.10) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.03). The company had revenue of $0.39 million for the quarter, compared to analyst estimates of $0.40 million. As a group, sell-side analysts predict that Dyadic International, Inc will post -0.31 earnings per share for the current year.
In related news, VP Ronen Tchelet sold 20,000 shares of the company’s stock in a transaction on Monday, June 17th. The shares were sold at an average price of $6.11, for a total value of $122,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders sold 40,000 shares of company stock valued at $238,300. 23.90% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in DYAI. NEXT Financial Group Inc acquired a new stake in Dyadic International during the second quarter valued at $50,000. Advisor Group Inc. acquired a new stake in Dyadic International during the second quarter valued at $222,000. Cedar Brook Financial Partners LLC acquired a new stake in Dyadic International during the second quarter valued at $314,000. Acadian Asset Management LLC acquired a new stake in Dyadic International during the second quarter valued at $50,000. Finally, Northeast Financial Consultants Inc acquired a new stake in Dyadic International during the second quarter valued at $1,565,000. Institutional investors and hedge funds own 7.88% of the company’s stock.
Dyadic International Company Profile (NASDAQ:DYAI)
Dyadic International, Inc, a biotechnology platform company, engages in the development, production, and sale of enzymes and other proteins in the United States and the Netherlands. It utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial production of human and animal vaccines, monoclonal antibodies, bi-specific antibodies, fab antibody fragments, FC-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins.
Read More: Death Cross
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.